Retained Earnings (Accumulated Deficit) of Dianthus Therapeutics, Inc. /DE/ from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Dianthus Therapeutics, Inc. /DE/ Retained Earnings (Accumulated Deficit) for the quarter ending 31 Dec 2025 was $336,729,000, a 93% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

Dianthus Therapeutics, Inc. /DE/ Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $336,729,000 -$162,337,000 -93% 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 $272,297,000 -$126,345,000 -87% 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $235,532,000 -$114,754,000 -95% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $203,903,000 -$100,732,000 -98% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $174,392,000 -$84,969,000 -95% 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 $145,952,000 -$67,092,000 -85% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $120,778,000 +$313,705,000 +72% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $103,171,000 +$328,028,000 +76% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $89,423,000 -$43,555,000 -95% 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $78,860,000 +$40,000 +0.05% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $434,483,000 -$68,695,000 -19% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $431,199,000 -$82,682,000 -24% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $45,868,000 -$28,476,000 -164% 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $78,900,000 +$227,375,000 +74% 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $365,788,000 -$76,940,000 -27% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $348,517,000 -$76,597,000 -28% 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $17,392,000 +$237,039,000 +93% 31 Dec 2021 8-K 21 Dec 2023
Q3 2021 $306,275,000 -$70,012,000 -30% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $288,848,000 -$70,263,000 -32% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $271,920,000 -$72,414,000 -36% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $254,431,000 -$74,936,000 -42% 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 $236,263,000 -$80,005,000 -51% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $218,585,000 -$83,317,000 -62% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $199,506,000 -$81,946,000 -70% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $179,495,000 -$76,769,000 -75% 31 Dec 2019 10-K 03 Mar 2021 2020 FY
Q3 2019 $156,258,000 -$70,211,000 -82% 30 Sep 2019 10-Q 13 Nov 2019 2019 Q3
Q2 2019 $135,268,000 -$65,236,000 -93% 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $117,560,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $102,726,000 -$57,515,000 -127% 31 Dec 2018 10-K 03 Mar 2020 2019 FY
Q3 2018 $86,047,000 30 Sep 2018 10-Q 08 Nov 2018 2018 Q3
Q2 2018 $70,032,000 30 Jun 2018 10-Q 09 Aug 2018 2018 Q2
Q4 2017 $45,211,000 31 Dec 2017 10-K 19 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.